September 2, 2024
NuCana Terminates Mid-Stage Colorectal Cancer Trial Due to Disappointing Results
NuCana, colorectal cancer, chemotherapy derivative, mid-stage trial, disappointing results
FDA Establishes AI Council to Oversee Ongoing and Future AI Projects
FDA, AI Council, Digital Health Advisory Committee, Artificial Intelligence, Machine Learning, Regulatory Guidance
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal